#United States #New York #The Gross Law Firm #Sarepta Therapeutics #SRPT

Important Notice for Sarepta Therapeutics Shareholders

The Gross Law Firm has officially informed shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) regarding a crucial deadline pertaining to a lead plaintiff appointment. This notice serves as a reminder that shareholders who purchased shares within the specified class period should take action by August 25, 2025.

Class Period and Allegations

The class period in question spans from June 22, 2023, to June 24, 2025. During this time frame, allegations have surfaced suggesting that Sarepta Therapeutics issued materially false and misleading statements. Key points of concern include:

1. Safety Risks Associated with ELEVIDYS: The lawsuit claims that ELEVIDYS, a prescription gene therapy for Duchenne, poses substantial safety risks to patients. This raises questions about the therapy's efficacy and the company’s transparency.
2. Failures in Clinical Trials: It is alleged that the trial regimes and protocols for ELEVIDYS did not adequately identify severe side effects, leading to misinformation regarding patient safety.
3. Regulatory Scrutiny: According to the allegations, the severity of adverse events linked to ELEVIDYS led to a halt in recruitment and dosing during trials, attracting significant regulatory attention and amplifying concerns about the therapy's approval processes.
4. Misrepresentation: As a result of these issues, the lawsuit posits that the company misled investors regarding their product's prospects and market status.

These allegations paint a concerning picture of Sarepta Therapeutics' handling of its obligations to both patients and investors, undermining their claims about the success of ELEVIDYS therapies.

Next Steps for Shareholders

Shareholders who purchased SRPT during the class period are strongly urged to register for this class action by visiting the Gross Law Firm's dedicated site. It is important to note that you do not need to be appointed as a lead plaintiff to participate in the potential recovery.

Once registered, shareholders will gain access to portfolio monitoring software that will keep them updated on the progression of the case. The firm emphasizes the urgency of registering before the August 25, 2025, deadline to ensure your interests are represented.

Why Choose Gross Law Firm?

The Gross Law Firm stands out as a nationally recognized class action firm focused on protecting the rights of investors impacted by fraudulent practices. Their mission entails advocating for investors' rights and ensuring that companies adhere to responsible business practices. With a commitment to recovering losses incurred by shareholders due to misleading statements and omissions, their work is vital in holding corporations accountable for their actions.

For additional questions or assistance, shareholders can reach out to The Gross Law Firm directly at:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: info@grosslawfirm.com
• - Phone: (646) 453-8903

Stay informed and take the necessary steps to protect your investments.